FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug

Why It Matters

Early access gives patients with limited options a potential new therapy and signals the FDA’s commitment to fast‑track life‑saving oncology treatments, potentially shortening the drug’s path to market.

Key Takeaways

• FDA granted expanded access for daraxonrasib within two days
• Daraxonrasib targets KRAS mutations in metastatic pancreatic cancer
• Drug holds Breakthrough Therapy, Orphan, and national priority voucher designations
• Revolution Medicines aims to file NDA later this year

Pulse Analysis

Pancreatic ductal adenocarcinoma remains one of the deadliest solid tumors, with five‑year survival under 10 percent and few effective systemic options after first‑line therapy fails. The U.S. Food and Drug Administration’s expanded access pathway lets physicians obtain investigational drugs for patients who have exhausted approved treatments, bypassing the lengthy enrollment of a clinical trial. By issuing a “safe to proceed” letter to Revolution Medicines on April 30, the agency opened a treatment channel for metastatic PDAC patients, underscoring its willingness to accelerate life‑saving therapies.

Daraxonrasib, also known as RMC‑6236, is a next‑generation RAS inhibitor that blocks the KRAS protein—a driver mutation present in roughly 90 % of pancreatic tumors. The compound already earned Breakthrough Therapy and Orphan Drug designations, reflecting early clinical promise and its potential to address an unmet medical need. In October 2025 the FDA awarded the drug a national priority voucher under the Commissioner’s pilot program, a mechanism that can fast‑track review and grant market exclusivity benefits. Revolution Medicines plans to submit a new drug application later this year, leveraging the voucher to shorten the approval timeline.

The rapid two‑day turnaround from request to approval highlights a shift toward more agile regulatory responses for high‑mortality cancers. For investors, the expanded access program not only offers a near‑term revenue stream but also generates real‑world data that can strengthen the forthcoming NDA. Competitors developing KRAS‑targeted agents will watch the outcome closely, as positive safety signals could reshape standard‑of‑care algorithms. Ultimately, broader patient access to daraxonrasib may improve survival outcomes while setting a precedent for future accelerated pathways in oncology.